Key Points
- Insider sale: Khurram Jamil sold 121,117 shares of Galectin Therapeutics on Nov. 13 at an average price of $5.47 for about $662,510, cutting his stake by 96.43% to 4,479 shares.
- Stock and earnings: GALT recently traded near $5.51 (50-day avg $5.00, 200-day avg $3.39) and reported a Q loss of ($0.13) per share vs. ($0.11) expected; market cap is roughly $355M and the 52-week range is $0.73–$6.55.
- Analyst and institutional backdrop: Analysts are split (consensus "Hold" with a $6 average target), and institutional ownership is modest at about 11.68% amid several recent new or increased positions by hedge funds.
Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) insider Khurram Jamil sold 121,117 shares of Galectin Therapeutics stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $5.47, for a total value of $662,509.99. Following the completion of the sale, the insider owned 4,479 shares in the company, valued at $24,500.13. This represents a 96.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Galectin Therapeutics Stock Performance
Shares of NASDAQ GALT traded down $0.02 during mid-day trading on Friday, reaching $5.51. 238,869 shares of the company's stock were exchanged, compared to its average volume of 390,645. The firm has a market capitalization of $355.28 million, a price-to-earnings ratio of -8.61 and a beta of 0.86. Galectin Therapeutics Inc. has a 52-week low of $0.73 and a 52-week high of $6.55. The company's 50-day moving average is $5.00 and its 200-day moving average is $3.39.
Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last posted its earnings results on Friday, November 14th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). As a group, equities analysts predict that Galectin Therapeutics Inc. will post -0.73 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of GALT. Ancora Advisors LLC raised its holdings in shares of Galectin Therapeutics by 302.9% in the third quarter. Ancora Advisors LLC now owns 52,380 shares of the company's stock valued at $222,000 after buying an additional 39,380 shares during the last quarter. Virtu Financial LLC acquired a new position in Galectin Therapeutics in the 3rd quarter valued at about $165,000. Two Sigma Investments LP purchased a new stake in Galectin Therapeutics during the 3rd quarter valued at approximately $70,000. Jefferies Financial Group Inc. acquired a new stake in Galectin Therapeutics during the 3rd quarter worth approximately $73,000. Finally, GSA Capital Partners LLP purchased a new position in shares of Galectin Therapeutics in the 3rd quarter valued at approximately $369,000. 11.68% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of equities research analysts have issued reports on GALT shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Galectin Therapeutics in a research report on Wednesday, October 8th. HC Wainwright reaffirmed a "buy" rating and issued a $6.00 target price on shares of Galectin Therapeutics in a research report on Thursday, August 14th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $6.00.
Read Our Latest Analysis on Galectin Therapeutics
About Galectin Therapeutics
(
Get Free Report)
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
